Table 3 Treatment outcome
From: Is podocytopathy another image of renal affection in p-SLE?
Treatment outcome | Group I (LN) cases n% = 79 (100%) | Group II (LP) cases n% = 7 (100%) | Test | P-value |
|---|---|---|---|---|
Treatment | ||||
Current steroid dose (mg/day) | ||||
(Mean ± SD) | 20.12 ± 16.70 | 15.00 ± 7.40 | t: 0.340 | 0.02* |
Hydroxychloroquine (n%) | 75 (94.9%) | 7 (100%) | ||
MMF (n%) | 46 (58.2%) | 3 (42.9%) | X2: 3.124 | 0.014* |
Cyclophosphamide (n%) | 12 (15.2%) | 0 | ||
Azathioprine (n%) | 10 (12.7%) | 2 (28.6%) | ||
Cyclosporine A (n%) | 4 (5.1%) | 2 (28.6%) | ||
Time of complete remission (weeks) (Mean ± SD) | 9.50 ± 6.56 | 3.40 ± 1.95 | t: 9.327 | 0.001* |
Number of relapses (Median, IQR) | 0 (0–1) | 1 (0–3) | U: 0.564 | 0.001* |